Upstream Bio, Inc. Common Stock
$5.33
-$0.15 (-2.74%)
$5.27Day Range$5.54
Key Statistics
Market Cap
$291.93M
Shares Outstanding
54.8M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 11, 2024
Round Lot
100
Locale
US
Trading Data
Day Open
$5.49
Day High
$5.54
Day Low
$5.27
Volume
497.2K
VWAP
$5.38
Prev Close
$5.48
Transactions
--
Acc. Volume
--
About Upstream Bio, Inc. Common Stock
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
PHARMACEUTICAL PREPARATIONSSIC 283475 employees890 WINTER STREET, SUITE 200, WALTHAM, MA, 02451781-208-2466IPO Oct 11, 2024US / STOCKSActiveWebsite
Identifiers
- CIK
- 0002022626
- Composite FIGI
- BBG017Y2X923
- Share Class FIGI
- BBG017Y2X950
- Ticker Root
- UPB
- SIC Code
- 2834
About Upstream Bio, Inc. Common Stock (UPB) Stock
Upstream Bio, Inc. Common Stock (UPB) closed the 2026-09-16 session at $5.33, down 2.74% versus the previous close (-0.15). The stock opened at $5.49 and traded between $5.27 and $5.54 during that session. Session trading volume was 497K shares. The volume-weighted average price (VWAP) is $5.38.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
Upstream Bio, Inc. Common Stock has a market capitalization of $291.9 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. UPB is listed on the XNAS exchange. The company employs approximately 75 people. Upstream Bio, Inc. Common Stock is headquartered in WALTHAM, MA. The recorded listing date is 2024-10-11.
On this page you can find market UPB stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.